MCM
REGN icon

Monument Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Monument Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-19
Closed -$8K – 266
2018
Q3 		$8K Buy
+19
New +$7.23K ﹤0.01% 183

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Monument Capital Management's REGN Position: Q4 2018 in Review

Monument Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2018, closing a stake of 19 shares — an estimated $8K sold.

Monument Capital Management first reported a position in REGN in Q3 2018 and held it in 1 quarter. The position peaked at $8K in Q3 2018. 670 funds tracked by Wall St. Rank hold REGN as of Q4 2018.

  • Monument Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Monument Capital Management sold 19 Regeneron Pharmaceuticals shares in Q4 2018, an estimated $8K.
  • Monument Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Monument Capital Management's Regeneron Pharmaceuticals position peaked at $8K in Q3 2018.
  • 670 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2018.

Based on Monument Capital Management's 13F filing for Q4 2018, filed 15 Jan 2019.